Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Shanghai's Stemirna Raises $14 Million for RNA Drug Development

publication date: Aug 12, 2019

Stemirna Therapeutics, a Shanghai RNA biopharma, raised nearly $14 million in a Series A financing. Founded in 2016 by a group of returning PhDs from MD Anderson Cancer Center in Houston, the company uses its proprietary Core Shell Structure Platform for mRNA Vaccines (LPP/mRNA®) to discover new drug candidates. Currently, Stemirna is developing more than a dozen mRNA drug projects that are either mRNA personalized cancer vaccines or vaccines for infectious disease, protein defects or genetic diseases. The company claims to be the first and only platform-based mRNA R&D enterprise in China. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020